• Optiscan completes first prototype to collect images from the GI tract
• Initiates pre-clinical GI study with University Medical Center Mainz, Germany
• Study to assess Optiscan's Gen2 real-time imaging capability on GI tract tissue

Optiscan Imaging Ltd (ASX:OIL) has announced the completion of the first prototype to collect images from the gastrointestinal (GI) tract, as well as the commencement of an important pre-clinical GI study with University Medical Centre of the Johannes Gutenberg University Mainz, Germany. The study aims to capture images of the GI tract, which will be used to assess the real-time imaging capability of Optiscan's Gen2 technology in diagnosing and treating GI diseases, including cancer, and progress planning for the upcoming clinical phase. This staged approach to collecting pre-clinical and then clinical data with the Gen2 prototype will assist Optiscan engineers in the development of the Company's Gen3 flexible endomicroscope, which will be used in future clinical trials. The study will also allow collection of imaging datasets of various disease processes to assist with initiation of AI algorithm development by the Company's CRC-P partner, Monash University. GI diseases pose a major global health challenge, and Optiscan's technology has the potential to enable clinicians to visualize and assess GI tissues with unprecedented clarity during screening procedures, facilitating immediate identification of abnormalities and enabling more precise interventions.

Optiscan is working towards receiving ethical clearance for the clinical phase of its planned studies, and will update the market once achieved. The partnership with Professor Kiesslich and his team represents a pivotal step forward in extending the capabilities of Optiscan's real-time, high-resolution imaging technology, as the Company plans to re-enter the GI endoscopy market with its own private label device.